Thyroid cancers exist in several forms. Providers caring for patients with thyroid cancer
must tailor the evaluation, treatment, and surveillance to the specific type and each
individual patient's risk factors for recurrence and mortality. Newer molecular diagnostics
and targeted therapies offer patients the potential for tailored, or personalized thyroid
cancer therapy. However, the risk of complications versus any potential benefit must be
weighed carefully since most thyroid cancers behave indolently, and complications could
be life-long.